Atopic dermatitis
Disease4 papers4 findings
- Humans2
Interventions
1Adoptive transfer of NK2 cells
downin mice1Low certainty
1 study
Adoptive transfer of NK2 cells
downin mice1Low certainty
Adoptive transfer of NK2 cells decrease atopic dermatitis in mice.
Animalsin aged mice
Age-related changes of FCGR3A⁺ natural killer cells and their association with elderly atopic dermatitis · EBioMedicine · 22 Sep 2026
Effects
1FCGR3A+ natural killer cells
downin humans1
1 study
FCGR3A+ natural killer cells
downin humans1
Atopic dermatitis decreases FCGR3A+ natural killer cells in humans.
Humansin eAD lesions
Age-related changes of FCGR3A⁺ natural killer cells and their association with elderly atopic dermatitis · EBioMedicine · 22 Sep 2026
Associations
2Bone fracture
upin humans1OR 1.08
1 study
Bone fracture
upin humans1OR 1.08
Atopic dermatitis is associated with bone fracture in humans (OR 1.08).
“associated AD with osteoporosis (odds ratio [OR], 1.56) and any fracture (OR, 1.08), although heterogeneity was substantial.”
Review
Atopic Dermatitis and Bone Fragility: Osteoimmunological Pathways, Therapeutic Paradoxes, and Risk-Adapted Screening Across the Lifespan · Preprints.org · 3 Sep 2026 · Preprint
Osteoporosis
upin humans1OR 1.56
1 study
Osteoporosis
upin humans1OR 1.56
Atopic dermatitis is associated with osteoporosis in humans (OR 1.56).
“A recent cohort-based meta-analysis associated AD with osteoporosis (odds ratio [OR], 1.56) and any fracture (OR, 1.08), although heterogeneity was substantial.”
Review
Atopic Dermatitis and Bone Fragility: Osteoimmunological Pathways, Therapeutic Paradoxes, and Risk-Adapted Screening Across the Lifespan · Preprints.org · 3 Sep 2026 · Preprint
Trial sponsors
Company1 trialPhase 3154 people
Company1 trialPhase 140 people
Company1 trialPhase 114 people
Company1 trialEarly phase 121 people
Murdoch Childrens Research Institute
1 trialPhase 413 people
National Hepatology & Tropical Medicine Research Institute
1 trialPhase 392 people
National Taiwan University Hospital
1 trialPhase 2/348 people
National Institute of Allergy and Infectious Diseases
2 trialsPhase 283 people